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Abstract
BACKGROUND: Iron overload is the main cause of oxidative stress in beta-thalassemia (βT) by the increased 
production of free radicals and reactive oxygen species. Antioxidants counteract the toxic effects of oxidative stress.
AIM: This study aims to evaluate the total antioxidant capacity (TAC) and the possible impact of splenectomy, iron 
chelators, and hydroxyurea (hydra) on serum level of TAC.
MATERIALS AND METHODS: Fifty children and adolescents with βT were studied in comparison to 25 healthy 
age- and sex-matched subjects. Complete medical history, clinical examination, and laboratory assessment of serum 
TAC, ferritin, hepcidin, and hemoglobin (Hb)  were carried out.
RESULTS: There was no statistically significant difference between the three groups; thalassemia major (TM), 
thalassemia intermedia (TI), and controls as regard age and sex. β-TM patients had significantly higher serum 
ferritin, serum hepcidin, and serum TAC (p < 0.000, 0.002, and 0.000, respectively) than controls. β-TI patients had 
significantly higher serum ferritin and serum TAC (p < 0.000) than controls. Serum TAC was lower in children with 
splenectomy, but this difference was not statistically significant. In addition, we observed no statistically significant 
difference in serum TAC of patients under different (deferasirox or deferiprone) medication. Serum TAC concentration 
was significantly higher in patients taking hydroxyurea (hydra) (p < 0.010).
CONCLUSIONS: The study showed an increased level of serum TAC in patients with β-T in comparison with 
controls. Serum TAC was also increased in those taking hydroxyurea, however, it was low in βT patients under 
regular chelation therapy, while splenectomy had no significant effect on serum TAC.
Introduction
Thalassemia is a genetic disease that leads 
to impaired globin chains and severe oxidative stress. 
In Egypt, clinical management of patients with beta-
thalassemia (βT) major depends mainly on blood 
transfusion (BT) and chelation therapy [1], [2]. However, 
iron overload is the main complication after long-term 
treatment [3]. Iron overload leads to peroxidative 
damage through increased production of free radicals 
and reactive oxygen species and is the main cause of 
oxidative stress [4]. Indirect bilirubin and uric acid are 
the main endogenous antioxidants, while both Vitamin E 
and ascorbic acid are important exogenous antioxidants. 
These antioxidants counteract the toxic effects of 
oxidative stress [5]. Different studies have evaluated 
oxidative stress biomarkers in various disorders, along 
with hemolytic anemia [5], [6], [7], [8], [9]. Moreover, 
genetic mutations in the Mediterranean population may 
result in different responses to oxidative stress [10]. 
Oxidative stress occurs along with a decrease in total 
antioxidant capacity (TAC) [11]. On the other hand, iron 
chelation regimen for BT patients can be helpful in the 
regulation of the antioxidant status in those patients [12].
The aim of this study was to evaluate TAC and the 
possible impact of splenectomy, different iron chelators, 
and hydroxyurea (hydra) on serum level of TAC.
Materials and Methods
The current case–control study was conducted 
in Pediatrics Clinic in Centre of Excellence in National 
Research Centre and El Helal Giza Children Hospital 
Hematology Clinic in 2019. The study included 
50 patients (30 thalassemia major [TM] and 20 
thalassemia intermedia [TI]). Another group of 25, 
age- and sex-matched healthy subjects were enrolled 
as a control group. The study was performed in 
accordance with the Helsinki Declaration for human 
research, and the study protocol was approved by the 
National Research Centre Ethics Committee. Inclusion 
criteria were Age >5 years <18 years, absence of 
cardiac, renal disease, and any chronic disease. The 
exclusion criteria were patients with a history of any 
recent infection or surgery, congestive heart failure, 
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moderate or high liver enzymes as well as positive viral 
hepatitis as hepatitis C or B, and patients on antioxidant 
medications. Data were collected by reviewing medical 
records as well as patient interviewing where detailed 
history taking and thorough clinical examinations were 
carried out. Blood was collected before BT.
Laboratory investigation
Sample collection
Four milliliters of venous blood were withdrawn 
under aseptic conditions, blood was centrifuged to get 
serum to measure liver function and kidney function 
tests. Serum samples were stored in −80°C for the 
assessment of serum ferritin, hepcidin, and serum TAC.
Liver function and kidney function tests were 
done using an autoanalyzer Olympus AU400 (Olympus 
America Inc., Center Valley, PA, USA). Serum ferritin and 
hepcidin were measured by ELISA assay (Bioneovan 
Co., Ltd., Beijing, China)
Serum total antioxidants capacity (TAC) was 
colorimetrically measured according to the methods 
described by Koracevic et al. [13].
Statistical analysis
Data analysis was carried out using the standard 
computer program Statistical Package for the Social 
Sciences (SPSS) for Windows, release 17.0 (SPSS Inc., 
USA). All numeric variables were expressed as mean ± 
standard deviation. The intergroup comparisons were 
performed using an independent -sample t-test and a 
one-way analysis of variance and Chi-square tests for 
categorical variables. Pearson’s and Spearman’s correlation 
tests (r = correlation coefficient) were used for correlating 
normal and non-parametric variables, respectively. For all 
tests, p < 0.05 was considered statistically significant.
Results
The mean age of the children with TM and TI was 
9.1 ± 3.8 years (from 5 to 18 years) and 10.2 ± 4.4 years 
(from 5 to 18 years old), respectively, with no statistically 
significant difference. Considering gender distribution, 
patients consisted of 29 (58%) boys and 21 (42%) girls, 
there was no statistically significant difference. β-TM 
patients had significantly higher serum ferritin, serum 
hepcidin, and serum TAC (p < 0.000, 0.002, and 0.000, 
respectively) than controls, while hemoglobin (Hb) and 
hepcidin/ferritin were significantly lower in patients than 
controls (p < 0.000 and 0.018, respectively), as shown 
in Table 1. β-TI patients had significantly higher serum 
ferritin and serum TAC (p < 0.000) than controls, while Hb 
and hepcidin/ferritin were significantly lower in patients 
than controls (p < 0.000 and 0.030, respectively), as 
shown in Table 2.
Table 1: Comparison between β-thalassemia major patients 
and controls
Cases and controls n Mean Std. deviation Sig. (two tailed)
Age (years)
β-TM patients 30 9.23 3.80 0.06 
Controls 25 10.24 4.45 
Hb (g/dL)
β-TM patients 30 6.59 0.948 0.000
Controls 25 11.76 1.012 
Ferritin (ng/mL)
β-TM patients 30 2099.10 574.50 0.000
Controls 25 142.92 59.137 
Hepcidin (ng/mL)
β-TM patients 30 21.74 13.11 0.002
Controls 25 12.53 6.69 
TAC (mmol/L)
β-TM patients 30 1.77 0.300 0.000
Controls 25 1.25 0.60 
Hepcidin/ferritin
β-TM patients 30 0.026 0.0576 0.018 
Controls 25 0.0916 0.037 
TAC: Total antioxidant capacity; TM: Thalassemia major; TI: Thalassemia intermedia; Hb: Hemoglobin.
Table 2: Comparison between β-thalassemia intermedia 
patients and controls
Cases and controls n Mean Std. deviation Sig. (two tailed)
Age (years)
β-TI patients 20 8.9000 3.98550 0.08 
Controls 25 10.24 4.45 
Hb (g/dL)
β-TI patients 20 7.8050 0.55010 0.000 
Controls 25 11.76 1.012 
Ferritin (ng/mL)
β-TI patients 20 958.1000 517.77468 .000
Controls 25 142.92 59.137 
Hepcidin (ng/mL)
β-TI patients 20 18.2225 14.37003 0.086 
Controls 25 12.53 6.69 
TAC (mmol/L)
β-TI patients 20 2.0300 0.22501 0.000 
Controls 25 1.25 0.60 
Hepcidin/ferritin
β-TI patients 20 0.021500 0.0213431 0.030 
Controls 25 0.0916 0.037 
TAC: Total antioxidant capacity; TM: Thalassemia major; TI: Thalassemia intermedia; Hb: Hemoglobin.
Demographic characteristics of thalassemia 
patients are shown in Table 3. 
Table 3: Demographic characteristics of thalassemia patients
Variable Patients (n=50)
Age (years) 9.1±3.8
Sex (male/female) 21/29
Number of patients TM and TI 30/20
Number of patients on chelation therapy (none/regular) 10/40 
Hydra intake (yes/no) 15/35
Splenectomized /non-splenectomized 14/36
Iron overload (serum ferritin ≥1000 ng/ml) 35/15
TM: Thalassemia major; TI: Thalassemia intermedia.
Figures 1 show boxplot of serum TAC in all 
groups.
Figure 1: Boxplot of serum total antioxidant capacity in β-thalassemia 
major, β-thalassemia intermedia, and controls
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Figures 2 shows boxplot of serum ferritin in all 
groups. Relation between total antioxidant capacity and 
ferritin in β-thalassemia major is shown in Figure 3.
Figure 2: Boxplot of serum ferritin in β-thalassemia major, 
β-thalassemia intermedia, and controls
Patients with β-TM had significantly higher 
ferritin ng/Ml (p < 0.001). While, β-TI had significantly 
higher level of Hb (g/dL) and TAC (mmol/L) (p < 0.001 
and < 0.002, respectively). Details are included in 
Table 4.
Table 4: Comparison of clinical and laboratory data of patients 
with β-thalassemia major and TI
Β-TM and Β-TI n Mean Std. deviation Sig. (two tailed)
Age (years)
β-TM 30 9.23 3.80 0.767
β-TI 20 8.90 3.98 
Hb (g/dL)
β-TM 30 6.59 0.948 0.001
β-TI 20 7.80 0.550  
Ferritin (ng/mL)
β-TM 30 2099.10 574.50 0.001
β-TI 20 958.10 517.77  
Hepcidin (ng/mL)
β-TM 30 21.74 13.11 0.375
β-TI 20 18.22 14.37  
TAC (mmol/L)
β-TM 30 1.77 0.30 0.002
β-TI 20 2.03 0.22  
Hepcidin/ferritin
β-TM 30 0.026 0.057 0.702
β-TI 20 0.0215 0.021  
TAC: Total antioxidant capacity; TM: Thalassemia major; TI: Thalassemia intermedia; Hb: Hemoglobin.
No correlation existed between TAC, age, and 
sex in thalassemia patients or controls. Interestingly, the 
observed reverse correlation between TAC and ferritin, 
Hb, hepcidin, and hepcidin-ferritin ratio in βT patients 
was not statistically significant. Details are included in 
Table 5.
Table 5: Correlations between serum concentrations of TAC and 
biochemical parameters in children with thalassemia and controls
Group Age, Y Ferritin,  
ng/mL 
Hemoglobin,  
g/dL
Hepcidin/ 
ferritin
Hepcidin,  
ng/mL
r p r p r p r p r p
β- 
Thalassemia M
0.134 0.481 −0.113 0.554 −0.088 0.644 −0.107 0.575 −0.166 0.379
β-TI 0.255 0.278 −0.472 0.026* −0.188 0.426 −0.119 0.616 −0.205 0.121
Controls 0.081 0.749 −0.270 0.202 0.022 0.919 0.219 0.304 −0.045 0.834
*correlation is significant at P value ≤ 0.05. TI: Thalassemia intermedia.
To evaluate the possible effect of several 
parameters on serum TAC in thalassemia children, 
samples were subdivided, as shown in Table 6. Serum 
TAC concentration was significantly higher in patients 
with no iron overload and those taking hydra (p < 0.001 
and 0.010), and TAC concentration was significantly 
lower in patients on chelating agents (p < 0.003). Serum 
value was lower in children with splenectomy, but this 
difference was not statistically significant. In addition, 
we observed no statistically significant difference in 
serum TAC of the patients under (deferasirox =DFX 
or deferiprone = DFP) treatment, as shown in Table 7. 
Furthermore, there were no statistically significant 
differences in serum TAC levels between males and 
females in patients with thalassemia (mean 1.89 ± 0.28 
and 1.86 mmol/L ± 0.31 mmol/L, respectively, p = 0.731).
Table 6: Comparison between the mean serum TAC (mmol/L) 
and several parameters in β-thalassemia patients
Item n TAC (mmol/L) Sig. (two tailed) 
Mean Std. deviation
Serum TAC (mmol/L)
No iron overload 15 2.08 0.185 0.001
Iron overload 35 1.79 0.296
Serum TAC (mmol/L)
Splenomegaly 36 1.89 0.268 0.608
Splenectomized 14 1.84 0.37151
Serum TAC (mmol/L)
Chelators 40 1.81 0.299 0.003
No 10 2.12 0.113
Serum TAC (mmol/L)
DFX 23 1.81 0.270 0.465
DFP 15 1.88 0.299
Serum TAC (mmol/L)
Hydra intake 15 2.04 0.206 0.010
No 35 1.80 0.306
Serum TAC (mmol/L)
Female
Male
19
21
1.89
1.86
0.285
0.310
0.731
DFX: Deferasirox; DFP: Deferiprone; Hydra: Oral hydroxyurea; TAC: Total antioxidant capacity; 
TM: Thalassemia major; TI: Thalassemia intermedia.
Table 7: Comparison between serum TAC (mmol/L) under 
different chelating agents in thalassemic patients
Group statistics
β-TM DFX and DFP n Mean Std. deviation Sig. (two tailed)
Serum TAC (mmol/L) DFX 18 1.7833 0.28128 0.500
DFP 10 1.8600 0.28363
β-TI DFX and DFP n Mean Std. deviation Sig. (two tailed)
Serum TAC (mmol/L) DFX 5 1.9400 0.20736 1.00
DFP 5 1.9400 0.35777
TAC: Total antioxidant capacity; TM: Thalassemia major; TI: Thalassemia intermedia; DFX: Deferasirox; 
DFP: Deferiprone.
Discussion
The use of frequent, regular BTs in β-TM 
patient has improved the span and quality of life, but 
increases chronic iron overload. This leads to oxidative 
stress in βT patients. This activates various antioxidant 
systems to protect the body from its damaging effects. 
In β-TI, it seems that hydra increases Hb levels and 
leads to transfusion independence, but it is not 
high enough to suppress bone marrow activity and 
ineffective erythropoiesis. Consequently, oxidative 
stress is increased.
There are controversial results about TAC 
in thalassemia patients. In the present study, we 
estimated TAC in serum, as several studies suggest 
that assessing TAC is more useful than measuring 
antioxidants individually, so their synergistic interactions 
could be evaluated [9], [13], [14], [15]. Our study showed 
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a significantly increased level of TAC in Egyptian 
β-TM and in β-TI patients. Bazvand et al. reported a 
significant increase in antioxidant status in Iranian βT 
patients when compared to normal controls [9]. Besides 
this, Karakas et al. reported that TAC was significantly 
increased in β-TM and β-TI [16]. It must be pointed out 
that another study showed decreased levels of TAC in 
Italian and Greek βT patients [5]. A possible explanation 
for this difference could be the different age ranges (41.5 
± 9.5 years) and/or different medications. Furthermore, 
genetic mutations in different population may result in 
different responses to oxidative stress [11]. A probable 
mechanism to explain the increased antioxidant status 
in patients with βT is the compensating antioxidant 
response due to excessive oxidative stress [16]. 
Endogenous antioxidants such as ferritin, bilirubin, and 
uric acid can result in increased level of TAC in patients 
with β-TM [9]. However, Cakmak et al. reported no 
significant differences in TAC between βT patients and 
controls [17].
Serum TAC concentration was significantly 
higher in βT patients with no iron overload than 
those with iron overload. Iron overload leads to 
peroxidative damage in β-TM and antioxidant systems 
try to decrease tissue damage by decreasing lipid 
peroxidation. Glutathione peroxidase levels were lower 
in iron overload patients as compared to controls [18].
In the present study, βT patients not receiving 
chelation therapy had significantly higher TAC compared 
with those on regular chelation. Metwalley and El-Saied 
reported that βT patients not receiving or on irregular 
chelation therapy had significantly lower TAC compared 
with those on regular chelation [19]. This difference 
could be explained by the fact that most patients not 
on chelation therapy in our study belong to the β-TI 
group who have significantly higher TAC concentration 
than β-TM group, probably due to less iron load and 
less oxidative stress. Likewise, this could explain 
the significantly higher TAC concentration in those 
taking hydra in our study. Aggressive regular chelation 
and antioxidant therapy should be used to cut the 
progression of the adverse effects of oxidative stress 
and to improve carbohydrate physiology in transfusion-
dependent β-TM [20]. Antioxidant therapy should be 
advised for thalassemia patients to improve glucose 
hemostasis [19].
There was no significant relationship between 
TAC and splenectomy status. Same result was reported 
by Karakas et al. [16]. No correlation existed between 
TAC and age, sex in thalassemia patients, or controls. 
Karakas et al. [16] reported the same results. Our 
results indicate that there was a negative non-significant 
correlation between TAC and ferritin. Different studies 
showed the same result [10,16].
Conclusions
The study showed an increased level of serum 
TAC in patients with βT in comparison with controls. 
Serum TAC was also increased in those taking 
hydroxyurea, however, it was low in βT patients under 
regular chelation therapy, while splenectomy had no 
significant effect on serum TAC.
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